Niagen Bioscience, Inc. (NAGE)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Niagen Bioscience, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 3.50 $ — 4% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
7/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 22.0%
- Exp. sales growth 3Y > 5% 12.0%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 19.4%
- Net debt < 4x EBIT -4.3x
- EBIT positive, 10Y straight 2
- Max. EBIT decline < 50% 0.0%
- Return on equity > 15% 24.5%
- ROCE > 15% 16.5%
- Expected return > 10% –
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
9 of 10 Growth gemTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 21.6% passed
- More than 10% revenue growth is expected for the coming year 17.3% passed
- Share count grows by less than 3% a year 7.0% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 40.1% passed
- Gross margin at 40% or higher and without meaningful erosion 64.3% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 62 m net cash passed
- Operating cash flow covers the profits of the last three years 12 m passed
- Return on capital at 15% or higher, or up versus two years ago 16.5% passed
- Insiders hold at least 10% or are net buyers 29.3% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 254.9% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 4
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.19 | 0.19 – 0.19 | 141 | 13.5% | 1 |
| 12/31/2027 | 0.29 | 0.29 – 0.29 | 162 | 52.6% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.03 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.09 | 5,690.60 | 29 | 37.40 | 24.60 | 9 | 9 |
| 2025: Q1 | 0.06 | – | 31 | 37.60 | 16.60 | 8 | 8 |
| 2025: Q2 | 0.04 | – | 31 | 36.80 | 11.60 | 1 | 1 |
| 2025: Q3 | 0.05 | 118.90 | 34 | 32.90 | 13.50 | 4 | 4 |
| 2025: Q4 | 0.05 | -44.30 | 34 | 16.20 | 12.20 | 1 | 1 |
| 2026: Q1 | 0.07 | 22.80 | 32 | 3.30 | 20.10 | -1 | -1 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 22 | -3 | -3 | -0.08 | -3 | 10 | 20 |
| 2017 | 21 | -16 | -11 | -0.26 | -10 | 54 | 63 |
| 2018 | 32 | -33 | -33 | -0.61 | -21 | 27 | 42 |
| 2019 | 46 | -31 | -32 | -0.56 | -20 | 20 | 40 |
| 2020 | 59 | -20 | -20 | -0.33 | -11 | 16 | 38 |
| 2021 | 67 | -27 | -27 | -0.40 | -24 | 32 | 58 |
| 2022 | 72 | -19 | -17 | -0.24 | -15 | 29 | 54 |
| 2023 | 84 | -6 | -5 | -0.07 | 7 | 28 | 55 |
| 2024 | 100 | 8 | 9 | 0.11 | 12 | 46 | 68 |
| 2025 | 129 | 14 | 17 | 0.20 | 13 | 77 | 106 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products.
| Employees | 117 |
|---|---|
| Headquarters | Los Angeles, CA |
| Address | 10900 Wilshire Blvd, 90024 Los Angeles, United States |
| Phone | 310 388 6706 |
| Website | niagenbioscience.com |
| IPO Date | 15. Jul 2008 |
| ISIN | US1710774076 |
| Stock Split | 1:3 on 04/13/2016 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Frank Louis Jaksch Jr. | Co-Founder & Chairman | 1968 |
| Robert N. Fried | CEO & Director | 1960 |
| Ozan Pamir C.F.A. | CFO & Principal Accounting Officer | 1992 |
| Carlos Lopez | Senior VP & General Counsel | 1981 |
| Andrew Shao Ph.D. | Senior Vice President of Global Regulatory & Scientific Affairs | – |
| Michiko Kelley | Chief Marketing Officer | – |
| Chu Yan | Managing Director of Asia Pacific | – |
| Kendall Knysch | Head of Media Relations & Partnerships | – |
| James Lee | Controller | 1976 |
| Wesley Yu | Vice President of Finance | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 30. Jun 2026 | Lopez Carlos Luis | SVP, General Counsel | Other | 2,314 | 2.71 | 6,271 |
| 30. Jun 2026 | Pamir Ozan | Chief Financial Officer | Other | 4,255 | 2.71 | 11,531 |
| 30. Jun 2026 | Fried Robert N | Chief Executive Officer | Other | 1,106 | 2.71 | 2,997 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.